10-Q: Functional Brands Secures $8M, Lists on Nasdaq, Resolves Debt

Functional Brands Inc. reported a profitable Q3 2025 driven by an ERTC refund, successfully listed on Nasdaq, and completed an $8 million private placement, significantly improving its financial position.

Summary

• Functional Brands Inc. reported net income of $259,001 for the three months ended September 30, 2025, a significant improvement from a net loss of $(288,081) in the prior year period.
• Revenue increased by 21% to $1,694,174 for the three months ended September 30, 2025, and by 5% to $5,116,963 for the nine months ended September 30, 2025, primarily due to increased direct-to-consumer sales.
• Gross profit margin improved to 57.7% for the three months and 55.0% for the nine months ended September 30, 2025.
• The company received a $491,801 Employee Retention Tax Credit (ERTC) reimbursement in September 2025, contributing substantially to the quarterly net income.
• As of September 30, 2025, cash balances increased significantly to $1,005,324 from $211,642 at December 31, 2024.
• Stockholders' equity moved from a deficit of $(118,577) at December 31, 2024, to a positive $604,665 at September 30, 2025.
• Subsequent to the quarter, the company completed a direct listing on the Nasdaq Capital Market under the ticker MEHA on November 5, 2025.
• A private placement closed on November 4, 2025, raising $8,000,000 in gross proceeds ($7,360,000 net) through the issuance of Series A and Series B Preferred Stock.
• The outstanding balance of $2,212,366 for the Kirkman acquisition was settled on November 14, 2025, with Kirkman Group assuming defense for related litigation.
• A convertible note with Emmis Capital II, LLC, with a principal balance of $234,000, was resolved on November 17, 2025, through a cash payment of $284,000, issuance of 50,000 common shares, and 50,000 Series C Warrants.
• The CEO and CFO concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to material weaknesses in internal control over financial reporting.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the successful Nasdaq listing, a substantial capital raise, and the resolution of significant outstanding liabilities (Kirkman acquisition payable and Emmis loan) post-quarter. While operating losses persist and internal controls are noted as ineffective, these strategic moves significantly de-risk the company's financial position and address the 'going concern' issue, providing a strong foundation for future growth. The one-time ERTC refund also boosted quarterly net income.

Positives

• Net income for the three months ended September 30, 2025, was $259,001, a substantial improvement from a net loss of $(288,081) in the same period last year.
• Revenue increased by 21% for the three months and 5% for the nine months ended September 30, 2025, driven by direct-to-consumer sales.
• Gross profit margin improved to 57.7% for the three months and 55.0% for the nine months ended September 30, 2025, indicating better cost controls and vendor terms.
• Cash balance significantly increased to $1,005,324 as of September 30, 2025, from $211,642 at December 31, 2024.
• Stockholders' equity turned positive to $604,665 as of September 30, 2025, from a deficit of $(118,577) at December 31, 2024.
• Net cash provided by operating activities for the nine months ended September 30, 2025, was $1,478,358, a significant increase from net cash used of $(54,178) in the prior year.
• Successful direct listing on the Nasdaq Capital Market (MEHA) on November 5, 2025.
• Completed an $8,000,000 gross private placement ($7,360,000 net) on November 4, 2025, providing significant capital.
• Settled the $2,212,366 outstanding balance for the Kirkman acquisition on November 14, 2025, resolving a major liability.
• Resolved a $234,000 convertible note with Emmis Capital II, LLC, on November 17, 2025, eliminating another debt obligation.

Negatives

• The company had a net loss of $(93,837) for the nine months ended September 30, 2025, despite the quarterly profit.
• Operating loss for the nine months ended September 30, 2025, worsened by 185% to $(265,823) from $(93,345) in the prior year.
• Interest expense increased significantly by 123% for the three months and 70% for the nine months ended September 30, 2025, due to increased loans.
• The company had negative working capital of $(1,491,727) and an accumulated deficit of $(7,754,767) as of September 30, 2025.
• The CEO and CFO concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to material weaknesses in internal control over financial reporting.
• High customer concentration, with two customers representing 63% of sales for the three months and 50% for the nine months ended September 30, 2025.
• Cash in excess of FDIC limits was approximately $507,664 as of September 30, 2025, posing a risk of loss or lack of access to funds.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to a net loss, negative working capital, and accumulated deficit, requiring additional capital raises.
• The company is significantly dependent on securing additional equity and/or debt financing, with no assurances of success.
• General business and economic conditions, consumer demand, and new FDA regulations could adversely affect financial condition and results of operations.
• High customer concentration means the loss of a few key customers could significantly impact revenue and financial performance.
• The company is involved in a contractual dispute with Trailer Park Boys Incorporated (TPB) regarding a license agreement, disputing $150,000 in minimum cash payments.
• Ongoing litigation with True Health Medical Center vs. Kirkman Group, with an uncertain outcome and potential for additional discovery and claims.
• Material weaknesses in internal control over financial reporting could adversely affect the company's ability to record, process, summarize, and report financial information reliably.

Future Outlook

Management believes that existing cash balances, combined with future capital raises through debt and equity, and cash receipts from product sales, will be sufficient to fund ongoing operations for at least one year from the financial statements' issuance date. The company is dependent on its ability to secure additional financing. The CEO's compensation structure includes performance-based equity awards tied to achieving positive EBITDA and market valuation milestones, indicating a focus on future profitability and growth.

Management Comments

• Management believes that its existing cash balances combined with future capital raises through debt and equity and cash receipts from product sales will be sufficient to fund ongoing operations through at least one year from the date the unaudited consolidated financial statements are issued.
• The CEO and CFO concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to the existence of material weaknesses in the company's internal control over financial reporting.
• Notwithstanding the material weaknesses, management believes that the unaudited consolidated financial statements and related financial information included in this Report fairly present in all material respects our financial condition, results of operations and cash flows as of the dates presented.

Industry Context

Functional Brands Inc. operates in the nutraceutical supplement industry, with a smaller segment in hemp-based consumer products. The primary focus on nutraceuticals (93% of revenue) suggests a stable market, but the company's reliance on direct-to-consumer sales and high customer concentration could be a differentiator or a vulnerability. The successful Nasdaq listing and capital raise position the company for potential growth and market expansion within its niche, especially as it addresses its 'going concern' issues. The industry is subject to FDA regulations, which the company acknowledges as a risk.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or industry benchmarks to assess the results against global standards. The company operates in the nutraceutical and hemp-derived product sectors, which have diverse market dynamics and competitive landscapes.

Management Changes

Corporate Governance

Legal Proceedings

• True Health Medical Center vs. Kirkman Group: True Health claims Kirkman underpaid royalties prior to asset sale to HTO Parties. True Health contends HTO Parties (Functional Brands' subsidiary) should be bound by the royalty agreement. Outcome is uncertain, and additional discovery is likely. Kirkman Group has undertaken to assume the defense for all defendants named in this litigation as of November 14, 2025.

Related Party Transactions

• Loans payable (related party) totaled $319,878 as of September 30, 2025, including a $130,000 loan at 20% annual interest (due March 11, 2031) and a $225,000 loan at 18% annual interest (due March 7, 2029).
• CEO Eric Gripentrog's employment agreement includes a base salary of $280,000 (increasing to $360,000 post-Nasdaq listing), annual cash bonuses based on revenue targets, and performance-based equity awards tied to acquisitions, positive EBITDA, and market valuation milestones. $105,000 was accrued for bonus payable during the nine months ended September 30, 2025.
• CFO Tariq Rahim's employment agreement includes $200,000 compensation, 27,265 restricted stock units (RSUs), 190,854 stock options, and performance-based stock payouts based on consolidated revenue targets.
• Exclusive license agreement with Trailer Park Boys Incorporated (TPB) for hemp-derived products, expiring December 31, 2025. The company has made $575,000 in minimum payments to date and accrued $75,000, but disputes the remaining $150,000 due to alleged unfulfilled obligations by TPB.

Stakeholder Impact

• Shareholders: The Nasdaq listing and successful private placement provide increased liquidity and capital, potentially boosting share value. However, the issuance of preferred stock and warrants could lead to future dilution. Material weaknesses in internal controls could impact investor confidence.
• Employees: Employment agreements for CEO and CFO include performance-based incentives, aligning management interests with company growth. Stock-based compensation was a significant expense.
• Customers: Increased direct-to-consumer sales indicate strong customer demand for nutraceutical products. High customer concentration poses a risk if key customer relationships deteriorate.
• Suppliers/Creditors: Settlement of the Kirkman acquisition payable and Emmis loan reduces major liabilities, improving the company's creditworthiness and ability to meet obligations. Line of credit agreements and other loans indicate ongoing reliance on debt financing.
• Regulatory Authorities: The company's status as an emerging growth company and smaller reporting company allows for certain exemptions, but the identified material weaknesses in internal controls will require attention to ensure compliance with SEC reporting standards.

Next Steps

• Continue efforts to secure additional equity and/or debt financing to fund ongoing operations.
• Address and remediate material weaknesses in internal control over financial reporting.
• Manage the ongoing contractual dispute with Trailer Park Boys Incorporated (TPB) regarding license payments.
• Monitor and manage the True Health Medical Center vs. Kirkman Group litigation, with Kirkman Group assuming defense.
• Focus on achieving positive EBITDA and market valuation milestones as outlined in the CEO's performance-based equity awards.

Key Dates

Recommendation

Functional Brands Inc. has made significant strides in addressing its 'going concern' issues and strengthening its financial foundation. The successful direct listing on Nasdaq provides enhanced visibility and liquidity. The $8 million private placement, coupled with the settlement of major acquisition payables and convertible debt, substantially improves the company's balance sheet and capital structure. While operating losses persist and internal control weaknesses are noted, these strategic financial maneuvers, along with revenue growth in its core nutraceutical business, indicate a positive inflection point. The company is now better positioned for future growth and stability, making it an attractive 'buy' for investors looking for a turnaround story with recent capital infusion and market access.

Keywords

Nutraceuticals, Supplements, Hemp Products, SEC Filing, 10-Q, Financial Results, Nasdaq Listing, Capital Raise, Private Placement, MEHA, Kirkman, Going Concern, Internal Controls, ERTC, Direct-to-Consumer